Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

A Novel, Orally Bioavailable Nociceptin Receptor Antagonist, LY2940094, Reduces Ethanol Self-Administration and Ethanol Seeking in Animal Models.

Rorick-Kehn LM, Ciccocioppo R, Wong CJ, Witkin JM, Martinez-Grau MA, Stopponi S, Adams BL, Katner JS, Perry KW, Toledo MA, Diaz N, Lafuente C, Jiménez A, Benito A, Pedregal C, Weiss F, Statnick MA.

Alcohol Clin Exp Res. 2016 May;40(5):945-54. doi: 10.1111/acer.13052. Epub 2016 Apr 16.

2.

Glutamatergic regulation of brain histamine neurons: In vivo microdialysis and electrophysiology studies in the rat.

Fell MJ, Flik G, Dijkman U, Folgering JH, Perry KW, Johnson BJ, Westerink BH, Svensson KA.

Neuropharmacology. 2015 Dec;99:1-8. doi: 10.1016/j.neuropharm.2015.05.034. Epub 2015 Jun 20.

PMID:
26100446
3.

Typical and atypical antipsychotic drugs increase extracellular histamine levels in the rat medial prefrontal cortex: contribution of histamine h(1) receptor blockade.

Fell MJ, Katner JS, Rasmussen K, Nikolayev A, Kuo MS, Nelson DL, Perry KW, Svensson KA.

Front Psychiatry. 2012 May 17;3:49. doi: 10.3389/fpsyt.2012.00049. eCollection 2012.

4.

Modulation of neurotransmitter release in orexin/hypocretin-2 receptor knockout mice: a microdialysis study.

Ortega JE, Katner J, Davis R, Wade M, Nisenbaum L, Nomikos GG, Svensson KA, Perry KW.

J Neurosci Res. 2012 Mar;90(3):588-96. doi: 10.1002/jnr.22781. Epub 2011 Oct 31.

PMID:
22038504
5.

N-(4-((2-(trifluoromethyl)-3-hydroxy-4-(isobutyryl)phenoxy)methyl)benzyl)-1-methyl-1H-imidazole-4-carboxamide (THIIC), a novel metabotropic glutamate 2 potentiator with potential anxiolytic/antidepressant properties: in vivo profiling suggests a link between behavioral and central nervous system neurochemical changes.

Fell MJ, Witkin JM, Falcone JF, Katner JS, Perry KW, Hart J, Rorick-Kehn L, Overshiner CD, Rasmussen K, Chaney SF, Benvenga MJ, Li X, Marlow DL, Thompson LK, Luecke SK, Wafford KA, Seidel WF, Edgar DM, Quets AT, Felder CC, Wang X, Heinz BA, Nikolayev A, Kuo MS, Mayhugh D, Khilevich A, Zhang D, Ebert PJ, Eckstein JA, Ackermann BL, Swanson SP, Catlow JT, Dean RA, Jackson K, Tauscher-Wisniewski S, Marek GJ, Schkeryantz JM, Svensson KA.

J Pharmacol Exp Ther. 2011 Jan;336(1):165-77. doi: 10.1124/jpet.110.172957. Epub 2010 Oct 14.

PMID:
20947638
6.

Activation of metabotropic glutamate (mGlu)2 receptors suppresses histamine release in limbic brain regions following acute ketamine challenge.

Fell MJ, Katner JS, Johnson BG, Khilevich A, Schkeryantz JM, Perry KW, Svensson KA.

Neuropharmacology. 2010 Mar;58(3):632-9. doi: 10.1016/j.neuropharm.2009.11.014. Epub 2009 Dec 3.

PMID:
19951716
7.

In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268).

Fell MJ, Perry KW, Falcone JF, Johnson BG, Barth VN, Rash KS, Lucaites VL, Threlkeld PG, Monn JA, McKinzie DL, Marek GJ, Svensson KA, Nelson DL.

J Pharmacol Exp Ther. 2009 Dec;331(3):1126-36. doi: 10.1124/jpet.109.160598. Epub 2009 Sep 15.

PMID:
19755662
8.

Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas.

Perry KW, Falcone JF, Fell MJ, Ryder JW, Yu H, Love PL, Katner J, Gordon KD, Wade MR, Man T, Nomikos GG, Phebus LA, Cauvin AJ, Johnson KW, Jones CK, Hoffmann BJ, Sandusky GE, Walter MW, Porter WJ, Yang L, Merchant KM, Shannon HE, Svensson KA.

Neuropharmacology. 2008 Oct;55(5):743-54. doi: 10.1016/j.neuropharm.2008.06.016. Epub 2008 Jun 17.

PMID:
18602930
9.

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders.

Rorick-Kehn LM, Johnson BG, Knitowski KM, Salhoff CR, Witkin JM, Perry KW, Griffey KI, Tizzano JP, Monn JA, McKinzie DL, Schoepp DD.

Psychopharmacology (Berl). 2007 Jul;193(1):121-36. Epub 2007 Mar 24.

PMID:
17384937
10.

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat.

Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP.

Neuropharmacology. 2006 May;50(6):755-60. Epub 2006 Jan 19.

PMID:
16427661
11.

Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine.

Tzavara ET, Bymaster FP, Overshiner CD, Davis RJ, Perry KW, Wolff M, McKinzie DL, Witkin JM, Nomikos GG.

Mol Psychiatry. 2006 Feb;11(2):187-95.

PMID:
16231039
12.

Case history: the discovery of fluoxetine hydrochloride (Prozac).

Wong DT, Perry KW, Bymaster FP.

Nat Rev Drug Discov. 2005 Sep;4(9):764-74. Review.

PMID:
16121130
13.

M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies.

Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, McKinzie DL, Felder C, Nomikos GG.

FASEB J. 2004 Sep;18(12):1410-2. Epub 2004 Jul 1.

PMID:
15231726
14.

Ontogenetic quinpirole treatments fail to prime for D2 agonist-enhancement of locomotor activity in 6-hydroxydopamine-lesioned rats.

Brus R, Kostrzewa RM, Nowak P, Perry KW, Kostrzewa JP.

Neurotox Res. 2003;5(5):329-38.

PMID:
14715452
15.
17.

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.

Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, Perry KW, Bymaster FP.

Neuropharmacology. 2003 Dec;45(7):935-44.

PMID:
14573386
18.

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG.

Br J Pharmacol. 2003 Feb;138(4):544-53.

19.

R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study.

Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP.

Neuropsychopharmacology. 2002 Dec;27(6):949-59.

20.

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW.

Neuropsychopharmacology. 2002 Nov;27(5):699-711.

21.

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex.

Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW.

Psychopharmacology (Berl). 2002 Apr;160(4):353-61. Epub 2002 Jan 29.

PMID:
11919662
23.

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Du Y, Ma Z, Lin S, Dodel RC, Gao F, Bales KR, Triarhou LC, Chernet E, Perry KW, Nelson DL, Luecke S, Phebus LA, Bymaster FP, Paul SM.

Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14669-74. Epub 2001 Nov 27.

24.

The cannabinoid CB(1) receptor antagonist SR141716A increases norepinephrine outflow in the rat anterior hypothalamus.

Tzavara ET, Perry KW, Rodriguez DE, Bymaster FP, Nomikos GG.

Eur J Pharmacol. 2001 Aug 31;426(3):R3-4.

PMID:
11527547
26.

The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex.

Perry KW, Nisenbaum LK, George CA, Shannon HE, Felder CC, Bymaster FP.

Biol Psychiatry. 2001 Apr 15;49(8):716-25.

PMID:
11313039
27.
28.

Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.

Zhang W, Perry KW, Wong DT, Potts BD, Bao J, Tollefson GD, Bymaster FP.

Neuropsychopharmacology. 2000 Sep;23(3):250-62.

30.
32.

Interactive modulation by dopamine and serotonin neurons of receptor sensitivity of the alternate neurochemical system.

Kostrzewa RM, Brus R, Perry KW.

Pol J Pharmacol. 1999 Jan-Feb;51(1):39-47. Review.

PMID:
10389143
33.

Olanzapine: a basic science update.

Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO.

Br J Psychiatry Suppl. 1999;(37):36-40. Review.

PMID:
10211140
34.

Olanzapine increases in vivo dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum.

Li XM, Perry KW, Wong DT, Bymaster FP.

Psychopharmacology (Berl). 1998 Mar;136(2):153-61.

PMID:
9551772
35.

Vasopressin/serotonin interactions in the anterior hypothalamus control aggressive behavior in golden hamsters.

Ferris CF, Melloni RH Jr, Koppel G, Perry KW, Fuller RW, Delville Y.

J Neurosci. 1997 Jun 1;17(11):4331-40.

38.
39.
40.
41.

Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.

Bymaster FP, Hemrick-Luecke SK, Perry KW, Fuller RW.

Psychopharmacology (Berl). 1996 Mar;124(1-2):87-94.

PMID:
8935803
42.

Antagonism of serotonin 5-HT1A receptors potentiates the increases in extracellular monoamines induced by duloxetine in rat hypothalamus.

Engleman EA, Robertson DW, Thompson DC, Perry KW, Wong DT.

J Neurochem. 1996 Feb;66(2):599-603.

PMID:
8592129
43.

Dopamine and 5-HT receptor sensitivity does not correlate with neostriatal dopamine or 5-HT content.

Kostrzewa RM, Brus R, Perry KW, Fuller RW.

Acta Neurobiol Exp (Wars). 1996;56(1):21-8.

44.

Serum corticosterone increases reflect enhanced uptake inhibitor-induced elevation of extracellular 5-hydroxytryptamine in rat hypothalamus.

Fuller RW, Perry KW, Hemrick-Luecke SK, Engleman E.

J Pharm Pharmacol. 1996 Jan;48(1):68-70.

PMID:
8722499
45.
46.

Tissue distribution, metabolism and effects of bufotenine administered to rats.

Fuller RW, Snoddy HD, Perry KW.

Neuropharmacology. 1995 Jul;34(7):799-804.

PMID:
8532147
48.
49.

Glucose and L-lactate metabolism in pregnant and in lactating ewes fed barley- or ground maize-based diets.

Perry KW, Janes AN, Weekes TE, Parker DS, Armstrong DG.

Exp Physiol. 1994 Jan;79(1):35-46.

50.

Proposed animal model of attention deficit hyperactivity disorder.

Kostrzewa RM, Brus R, Kalbfleisch JH, Perry KW, Fuller RW.

Brain Res Bull. 1994;34(2):161-7.

PMID:
7913871

Supplemental Content

Loading ...
Support Center